Reimagining a New Strategic Vision for ISPOR
Brian O’Rourke, PharmD, President, Brian O’Rourke Health Care Consulting, Inc, Ottawa, Canada; and ISPOR President (2023-2024), Lawrenceville, NJ, USA
I am honored to serve as your President. Thank you for trusting me with this considerable responsibility. The future is exciting—for our Society, for our careers as health economics and outcomes research (HEOR) professionals, and for the impact that HEOR continues to have on healthcare globally.
ISPOR’s global reach is wide, representing members from 110 countries including 19,000 individual and chapter members with 84 regional chapters and 143 student chapters. Members involved in our student chapters represent some of the best and brightest scientists, clinicians, and health economists—meaning our future is secure.
It is an incredibly exciting time for ISPOR. As the pandemic subsided, we gathered again in person in Boston, MA, USA this May with more than 4500 participants representing stakeholders from academia, pharmaceutical and medical device companies, consultancies, governments, payers, health technology assessment agencies, patient organizations, and others.
We are back!
"It is also a time of enormous opportunity for ISPOR and the broader HEOR community as we promote early and equitable access to innovative and affordable pharmaceuticals and health technologies—all with the goal of improving global health."
We recently welcomed Robert Abbott to the ISPOR family as our new CEO and Executive Director. As someone who was involved in the CEO selection, I am confident Rob will bring his passion for science, his knowledge and experience, his creativity, and his exceptional leadership skills to propel ISPOR successfully into the future.
It is also a time of enormous opportunity for ISPOR and the broader HEOR community as we support implementation of complex legislation; as we strive to better understand the role of digital health solutions; as we continue to advance our HEOR methods and processes; and as we promote early and equitable access to innovative and affordable pharmaceuticals and health technologies—all with the goal of improving global health.
"Reimagining HEOR will take a combination of evolutionary and revolutionary thinking and it will require increased collaboration and harmonization of our methods."
Over the coming months, the ISPOR Board of Directors will work with Rob Abbott and his incredible ISPOR staff to reimagine a new strategic vision for ISPOR. We will consult broadly and leverage past learnings, while capitalizing on new thinking. For example, the “Amplify HEOR” initiative that was recently launched will help to spread and scale the voice of HEOR with decision makers at all levels. We will also continue to elevate the science and practice of HEOR and look for ways to build health equity principles into everything we do.
Reimagining HEOR will take a combination of evolutionary and revolutionary thinking and will require increased collaboration and harmonization of our methods. I look forward to sharing details on our emerging strategic vision as we review, evaluate, and rewrite our strategic plan. Very exciting times are ahead!
